Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04129775 · ClinicalTrials.gov registry record · Phase 1

OTO-413 in Subjects With Speech-in-Noise Hearing Impairment

A Phase 1 study of Sensorineural Hearing Loss, sponsored by Otonomy.

Completed
Registry status
Phase 1
Development phase
110
Enrollment target
8
Study locations

NCT04129775 is a Phase 1 study of Sensorineural Hearing Loss that has completed, run by Otonomy. The registered enrollment target is 110 participants, below the 122-participant average among 13 other Sensorineural Hearing Loss trials with a reported enrollment target (10% lower). The trial reports 8 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04129775, a Phase 1 study of Sensorineural Hearing Loss, has completed, sponsored by Otonomy.

COMPLETED
Registry status
Phase 1
Development phase
110 participants
Enrollment target
8
Study locations

Study Summary

The purpose of this study is to evaluate the safety, tolerability, and exploratory efficacy of OTO-413 administered as an intratympanic injection for the treatment of speech-in-noise hearing impairment.

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG OTO-413

Study Locations (8)

Florida

  • Research Centers of America - Hollywood
  • South Florida ENT Associates or Research Centers of America - Miami
  • University of South Florida - Tampa

Colorado

  • Colorado Otolaryngology Associates LLC dba Colorado ENT & Allergy - Colorado Springs

Kentucky

  • Advanced ENT and Allergy, PLLC - Louisville

North Carolina

  • Piedmont Ear, Nose & Throat Associates - Winston-Salem

Utah

  • JBR Clinical Research - Salt Lake City

Virginia

  • Eastern Virginia Medical School, Department of Otolaryngology - Norfolk

Trial Details

FieldValue
Enrollment Target 110 participants
Start Date 2019-10-01
Est. Completion 2022-09-05
Phase Phase 1

Sponsor

Otonomy

20 total trials

What the Registry Record Tells You About NCT04129775

The ClinicalTrials.gov registry entry for NCT04129775 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 122-participant average among 13 other Sensorineural Hearing Loss trials with a reported enrollment target (10% lower). The listed sponsor is Otonomy, which has 20 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Sensorineural Hearing Loss appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT04129775 reports 8 study locations spanning 6 distinct geographic areas - top geographies include Florida, Colorado, Kentucky.

Frequently Asked Questions

What is clinical trial NCT04129775 about?

NCT04129775 is a clinical study titled "OTO-413 in Subjects With Speech-in-Noise Hearing Impairment". The purpose of this study is to evaluate the safety, tolerability, and exploratory efficacy of OTO-413 administered as an intratympanic injection for the treatment of speech-in-noise hearing impairment.

What is the current status of trial NCT04129775?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 110 participants. The study started on 2019-10-01. Estimated completion is 2022-09-05.

What conditions does trial NCT04129775 study?

This clinical trial studies the following conditions: Sensorineural Hearing Loss.

What interventions are being tested in trial NCT04129775?

The interventions under investigation include: Placebo (DRUG), OTO-413 (DRUG).

Who is sponsoring clinical trial NCT04129775?

This trial is sponsored by Otonomy, which has 20 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04129775 being conducted?

This trial has 8 study locations across Colorado, Florida, Kentucky, North Carolina, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Sensorineural Hearing Loss

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.